The primary endpoint of the study was to determine whether the addition of Empliciti to Revlimid and low-dose dexamethasone would improve progression-free survival. Credit: KGH.

Bristol Myers Squibb’s (BMS) ELOQUENT-1 Phase III trial evaluating the Empliciti combination in patients with newly diagnosed, previously untreated multiple myeloma has failed to meet the primary endpoint of progression-free survival (PFS) in patients ineligible for transplant.

The randomised, open-label trial analysed combinations of Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ERd), versus Revlimid and dexamethasone alone (Rd) in the subjects.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Empliciti is an immunostimulatory antibody that targets a cell-surface glycoprotein called Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7).

The company revealed that the addition of Empliciti did not find a statistically vital improvement in PFS in the final analysis.

Secondary endpoints of the ELOQUENT-1 Phase III trial were objective response rate and overall survival. The safety profile of ERd was observed to be generally consistent with the known profile of Empliciti plus Revlimid and dexamethasone.

Bristol Myers Squibb Hematology Global Clinical Development senior vice-president Noah Berkowitz said: “While we are disappointed that the ELOQUENT-1 trial did not meet its primary endpoint in these previously untreated, transplant-ineligible patients, the Empliciti, Revlimid and dexamethasone combination remains a standard treatment for patients with relapsed/refractory multiple myeloma, providing the potential for improved survival in this population of patients who are in need of additional treatment options.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Multiple myeloma is said to be an aggressive disease characterised by relapse and is prone to be refractory to several therapies.

BMS said that it will complete a full evaluation of the ELOQUENT-1 data and work with investigators to present the results at a future medical meeting.

The company is developing Empliciti with US biopharmaceutical company AbbVie.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact